Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant carboplatin + paclitaxel + tislelizumab for newly diagnosed ovarian cancer
ChiCTR2000040760Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, carboplatin and paclitaxel in ovarian cancer, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: CRS3 rate. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
tislelizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000040760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040760.